PerkinElmer said the transaction is expected to close by the end of 2021.

Photo: Marcio Jose Sanchez/Associated Press

PerkinElmer Inc. PKI 0.70% said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock.

PerkinElmer said Monday the transaction is expected to close by the end of the 2021 calendar year.

Privately held BioLegend has more than 700 employees based primarily in the U.S., with estimated 2022 revenues of $380 million, PerkinElmer said.

Upon joining PerkinElmer, BioLegend’s San Diego campus will become PerkinElmer’s global Center of Excellence for research reagent content development for the combined company.

The deal is expected to boost PerkinElmer’s existing revenue growth and profit margin profile, and add an estimated 30 cents of adjusted earnings a share in the first full year after closing the deal, and greater than 50 cents in the second year after closing.

The combined company will generate “immediate revenue synergies” that are expected to reach $100 million annually by the fifth year following the transaction close, and “no significant cost synergies are planned,” PerkinElmer said.

Also Monday, PerkinElmer reported earnings of $2.19 a share on revenue of $1.23 billion for the second quarter.

Write to Chris Wack at [email protected]

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Publicis Raises 2021 Revenue Forecast After Quarterly Growth

Publicis Groupe SA boosted its outlook for 2021 organic revenue growth thanks…

Spate of Mock News Sites With Russian Ties Pop Up in U.S.

Into the depleted field of journalism in America, a handful of websites…

Koch network faces internal scrutiny after Nikki Haley endorsement

The political branch of the powerful Koch network is facing scrutiny as…

‘Great Replacement’ rhetoric hints at Stefanik’s ambition. So does her changing district.

Those hard-liners will be keeping close tabs on her performance as she…